Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Smoldering Plasma Cell Myeloma”

115 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 115 results

Testing effectiveness (Phase 2)Looking for participantsNCT06100237
What this trial is testing

Teclistamab in Combination With Daratumumab for High-Risk Smoldering Myeloma: A Clinical and Correlative Phase 2 Immuno-Oncology Study (the REVIVE Study)

Who this might be right for
Multiple Myeloma
Carl Ola Landgren, MD, PhD 50
Very early researchActive Not RecruitingNCT02603887
What this trial is testing

Pembrolizumab in Treating Patients With Intermediate or High-Risk Smoldering Multiple Myeloma

Who this might be right for
Smoldering Plasma Cell Myeloma
M.D. Anderson Cancer Center 20
Not applicableNot Yet RecruitingNCT06987708
What this trial is testing

Evaluating the Impact of a 12-month Multi-Modal Lifestyle Management Intervention on Disease Relevant Biomarkers

Who this might be right for
Monoclonal Gammopathy of Uncertain SignificanceSmoldering Myeloma
Hackensack Meridian Health 67
Not applicableLooking for participantsNCT07214324
What this trial is testing

Integrative Multi-omics Analysis to Predict Monoclonal Gammopathies Clinical Evolution

Who this might be right for
Monoclonal Gammopathy of Undetermined Significance (MGUS)Smoldering Multiple Myeloma (SMM)Multiple Myeloma (MM)
Azienda USL Reggio Emilia - IRCCS 60
Testing effectiveness (Phase 2)Looking for participantsNCT05841550
What this trial is testing

The TG01 Study With TG01/QS-21 Vaccine in Patients With High-risk Smouldering Multiple Myeloma and Multiple Myeloma

Who this might be right for
Multiple MyelomaSmoldering Multiple Myeloma
Oslo University Hospital 20
Testing effectiveness (Phase 2)Ended earlyNCT00899353
What this trial is testing

Prevention of Disease Progression in Early Stage Indolent B Cell Malignancies. (SMM)

Who this might be right for
Monoclonal Gammopathy of Undetermined SignificanceSmoldering Multiple MyelomaChronic Lymphocytic Leukemia
Marshall University 16
Early research (Phase 1)Active Not RecruitingNCT02886065
What this trial is testing

PVX-410, a Cancer Vaccine, and Citarinostat +/- Lenalidomide for Smoldering MM

Who this might be right for
Smoldering Multiple Myeloma
Massachusetts General Hospital 19
Large-scale testing (Phase 3)Looking for participantsNCT03937635
What this trial is testing

Lenalidomide, and Dexamethasone With or Without Daratumumab in Treating Patients With High-Risk Smoldering Myeloma

Who this might be right for
Smoldering Plasma Cell Myeloma
ECOG-ACRIN Cancer Research Group 288
Testing effectiveness (Phase 2)Ended earlyNCT00942422
What this trial is testing

Green Tea Extract in Treating Patients With Monoclonal Gammopathy of Undetermined Significance and/or Smoldering Multiple Myeloma

Who this might be right for
Multiple Myeloma and Plasma Cell NeoplasmPrecancerous Condition
Barbara Ann Karmanos Cancer Institute 8
Large-scale testing (Phase 3)Study completedNCT03301220
What this trial is testing

Subcutaneous Daratumumab Versus Active Monitoring in Participants With High-Risk Smoldering Multiple Myeloma

Who this might be right for
Smoldering Multiple Myeloma
Janssen Research & Development, LLC 390
Not applicableStudy completedNCT06472778
What this trial is testing

A Real-world Study in Participants With Smoldering Multiple Myeloma

Who this might be right for
Smoldering Multiple Myeloma
Janssen-Cilag Ltd. 408
Large-scale testing (Phase 3)Study completedNCT00480363
What this trial is testing

QUIREDEX: Revlimid (Lenalidomide) and Dexamethasone (ReDex) Treatment Versus Observation in Patients With Smoldering Multiple Myeloma With High Risk of Progression

Who this might be right for
Multiple Myeloma
PETHEMA Foundation 120
Very early researchStudy completedNCT03631043
What this trial is testing

Personalized Vaccine in Treating Patients With Smoldering Multiple Myeloma

Who this might be right for
Smoldering Plasma Cell Myeloma
M.D. Anderson Cancer Center 30
Testing effectiveness (Phase 2)Ended earlyNCT02943473
What this trial is testing

Study on the Effect of Ibrutinib on High Risk Smoldering Multiple Myeloma Patients

Who this might be right for
High Risk Smoldering Multiple Myeloma
Icahn School of Medicine at Mount Sinai 9
Testing effectiveness (Phase 2)Looking for participantsNCT06762769
What this trial is testing

Isatuximab and Iberdomide as Immunotherapy for High Risk in Smouldering Myeloma

Who this might be right for
Smouldering Myeloma
University College, London 63
Testing effectiveness (Phase 2)Ended earlyNCT01838369
What this trial is testing

A Phase II Study of BI-505 in Smoldering Multiple Myeloma

Who this might be right for
Smoldering Multiple Myeloma
BioInvent International AB 4
Not applicableUnknownNCT04727294
What this trial is testing

MGUS, SMM, and MM Patient Experience With Coronavirus 19 (COVID-19) Survey

Who this might be right for
Multiple MyelomaSmoldering Multiple MyelomaMonoclonal Gammopathy of Undetermined Significance+1 more
HealthTree Foundation 1,500
Early research (Phase 1)Looking for participantsNCT05055063
What this trial is testing

With Extension Cohort, Single Arm, Single Center, Open Label Trial of Belantamab Mafodotin for the Treatment of High-Risk Smoldering Multiple Myeloma

Who this might be right for
Myeloma
M.D. Anderson Cancer Center 30
Testing effectiveness (Phase 2)Study completedNCT02903381
What this trial is testing

A Phase II Trial If Nivolumab, Lenalidomide and Dexamethasone in High Risk Smoldering Myeloma

Who this might be right for
Smoldering Multiple Myeloma
Dana-Farber Cancer Institute 8
Not applicableStudy completedNCT01955395
What this trial is testing

Genomic and Psychosocial Effects of the 3RP on Patients With MGUS and Smoldering Multiple Myeloma

Who this might be right for
Monoclonal Gammopathy of Undetermined SignificanceSmoldering Multiple Myeloma
Dana-Farber Cancer Institute 93
Next Page